![Michael Kelliher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 30/06/2026
Michael Kelliher currently works at Capricor Therapeutics, Inc., as Independent Director from 2023 and Ardelyx, Inc., as Chief Business Officer from 2025.
Mr. Kelliher also formerly worked at Horizon Therapeutics Ltd. (Ireland), as Group Vice President-Merger & Acquisition.
Mr. Kelliher received his undergraduate degree from University College Cork.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ARDELYX, INC. 0,14 % | 21/05/2026 | 357.418 ( 0,14 % ) | 2 M $ | 30/06/2026 |
| 28/02/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CAPRICOR THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/09/2023 |
| ARDELYX, INC. | Corporate Officer/Principal | 25/03/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Horizon Therapeutics Ltd. (Ireland)
 Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Discovers, develops and manufactures pharmaceuticals for autoimmune & inflammatory diseases | Health Technology |
University College Cork
 University College Cork Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Capricor Therapeutics, Inc.
 Capricor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of cardiovascular diseases | Health Technology |
Ardelyx, Inc.
 Ardelyx, Inc. Pharmaceuticals: MajorHealth Technology Discovers and Develops therapeutic therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
